摘要
分析莆田地区非小细胞肺癌(NSCLC)患者表皮生长因子受体(EGFR)基因突变的情况。收集138例莆田地区非小细胞肺癌组织,采用EliVisionTM plus免疫组织化学染色检测癌组织中EGFR基因外显子18、19、20及2l的突变,同时分析其突变与临床特征的关系。结果:138例NSCLC中共检出52例EGFR基因突变,EGFR突变阳性率为37.7%;外显子19和21突变占总突变的92.3%;腺癌突变发生率占突变总数的73.1%;女性EGFR基因突变率(55.0%)显著高于男性(30.6%)(P<0.05)。结果表明:莆田地区NSCLC患者EGFR基因突变以外显子19和21突变为主,女性患者和腺癌患者是选用EGFR酪氨酸激酶抑制剂的优势人群。
The incidence of mutations of epidermal growth factor receptor（EGFR） in the patients with non-small cell lung cancer（NSCLC） was investigated in Putian. In this study, 138 pathological specimen of NSCLC patients were collected in Putian area. Mutations of EGFR exons 18, 19, 20 and 21 were detected by amplification refractory mutation system（ARMS）. The relationship between the mutations of EGFR and clinical characters were analyzed. Mutation were found in 52 cases, with an incidence of 37.7 %. Mutations in exon 19 and 21 accounted for 92.3 % of total. Mutations in adenocarcinoma accounted for 73.1 % of total incidence of mutation, female EGFR mutation rate（55 %） was significantly higher than that in male（30.6 %）（P〈0.05）. NSCLC in Putian area was characterized by the mutation of the EGFR exon 19 and 21. Female patients and patients with adenocarcinoma may be the appropriate crowd to be treated with EGFR tyrosine kinase inhibitor.
出处
《莆田学院学报》
2014年第2期27-29,共3页
Journal of putian University
关键词
莆田
非小细胞肺癌
EGFR
基因突变
Putian
non-small cell lung cancer
epidermal growth factor receptor
gene mutation
